RIYADH: Saudi-based AJA Pharma has signed a Memorandum of Understanding with UAE’s Bioventure FZ-LLC to license and supply new pharmaceutical products.
According to a bourse filing, the new additional selected pharmaceutical products in the Middle East region are set to be used in the Saudi Export stand at the upcoming Arab Health Expedition 2023.
Under the terms of the new MoU, Bioventure, a subsidiary of GlobalOne Healthcare Holding, is set to focus and develop various delivery forms including complex-to-develop formulations, diabetes, oncology, and biosimilars.
Asian News is your digital newspaper keeping you updated with the current affairs from around the world.
Any kind of content updation or deletion, kindly email us at email@example.com